In last trading session, Sarepta Therapeutics Inc (NASDAQ:SRPT) saw 5.2 million shares changing hands with its beta currently measuring 0.61. Company’s recent per share price level of $35.74 trading at -$0.46 or -1.27% at ring of the bell on the day assigns it a market valuation of $3.51B. That closing price of SRPT’s stock is at a discount of -384.75% from its 52-week high price of $173.25 and is indicating a premium of 2.35% from its 52-week low price of $34.90. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 7.65 million shares which gives us an average trading volume of 3.05 million if we extend that period to 3-months.
For Sarepta Therapeutics Inc (SRPT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.44. Splitting up the data highlights that, out of 17 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 6 suggested the stock as a Hold whereas 10 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Sarepta Therapeutics Inc (NASDAQ:SRPT) trade information
Upright in the red during last session for losing -1.27%, in the last five days SRPT remained trading in the red while hitting it’s week-highest on Friday, 05/09/25 when the stock touched $35.74 price level, adding 9.88% to its value on the day. Sarepta Therapeutics Inc’s shares saw a change of -70.61% in year-to-date performance and have moved -2.67% in past 5-day. Sarepta Therapeutics Inc (NASDAQ:SRPT) showed a performance of -34.58% in past 30-days. Number of shares sold short was 6.7 million shares which calculate 2.43 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 156 to the stock, which implies a rise of 77.09% to its current value. Analysts have been projecting 110 as a low price target for the stock while placing it at a high target of 202. It follows that stock’s current price would drop -207.78% in reaching the projected high whereas dropping to the targeted low would mean a loss of -207.78% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around -171.95% while estimates for its earnings growth in next 5 years are of 61.61%.
Sarepta Therapeutics Inc (NASDAQ:SRPT)’s Major holders
Insiders are in possession of 4.41% of company’s total shares while institution are holding 89.98 percent of that, with stock having share float percentage of 94.14%. Investors also watch the number of corporate investors in a company very closely, which is 89.98% institutions for Sarepta Therapeutics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at SRPT for having 10.32 million shares of worth $1.63 billion. And as of 2024-06-30, it was holding 10.9117 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 9.04 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.5496 of outstanding shares, having a total worth of $1.43 billion.
On the other hand, GROWTH FUND OF AMERICA and iShares Trust-iShares Core S&P Mid-Cap ETF are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 3.15 shares of worth $112.58 million or 3.21% of the total outstanding shares. The later fund manager was in possession of 3.12 shares on Mar 31, 2025 , making its stake of worth around $111.51 million in the company or a holder of 3.17% of company’s stock.
